Pilot, Open-label Study of Safety and Tolerability of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)
Latest Information Update: 29 Mar 2023
At a glance
- Drugs QLS-101 (Primary)
- Indications Glaucoma; Ocular hypertension
- Focus Adverse reactions
- Sponsors Qlaris Bio
- 22 Mar 2023 Status changed from active, no longer recruiting to completed.
- 17 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 29 Nov 2022 Planned End Date changed from 28 Feb 2023 to 31 Mar 2023.